PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
A meta-analysis of four RCTs indicated that corn silk decoction is effective in improving the lipid profile in patients with angina pectoris [PMID:31423665].
Preliminary clinical trials show promise for anti-diabetic effects, though larger RCTs are needed [PMID:40437199].
Corn silk flavonoids exhibited uric acid-lowering activity in vitro and in vivo by inhibiting xanthine oxidase (XOD) and promoting uric acid excretion [PMID:37294890].
Acidic polysaccharides from corn silk (CSP-50E) showed significant hepatoprotective effects in vitro by reducing IL-6, TNF-α, AST, and ALT activity in ethanol-induced damaged liver cells [PMID:36863670].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 37294890 (2023) — Corn Silk Flavonoids Ameliorate Hyperuricemia via PI3K/AKT/NF-κB Pathway. · Journal of agricultural and food chemistry
- 2.PMID: 37187994 (2023) — Bioactive compounds of corn silk and their role in management of glycaemic response. · Journal of food science and technology
- 3.PMID: 40437199 (2025) — Unlocking Corn Silk's Potential: Bioactive Compounds Targeting Age-Related Diseases. · Molecular nutrition & food research
- 4.PMID: 40461278 (2026) — Field Preparation and Planting Corn (Zea mays). · Cold Spring Harbor protocols
- 5.PMID: 22890173 (2012) — Corn silk (Stigma maydis) in healthcare: a phytochemical and pharmacological review.